Progress on pharmaceutical characteristics of potassium-competitive acid blocker
10.12206/j.issn.2097-2024.202306040
- VernacularTitle:钾离子竞争性酸阻滞剂的药学特征研究进展
- Author:
Yaozhen WANG
1
,
2
;
Can XU
3
;
Shunli LV
3
;
Jing TIAN
3
;
Dongwei ZHANG
4
Author Information
1. The First Affiliated Hospital of the Naval Medical University: a. Department of Pharmacy, b. Department of Gastroenterology, Shanghai 200433, China
2. Department of Pharmacy, The Second Norman Bethune Hospital of Jilin University, Changchun 130041, China.
3. The First Affiliated Hospital of the Naval Medical University: a. Department of Pharmacy, b. Department of Gastroenterology, Shanghai 200433, China.
4. Department of Health Service, The Guard Bureau of the Joint Staff Department of PLA, Beijing 100017, China.
- Keywords:
potassium-competitive acid blocker;
acid-related diseases;
progress
- From:
Journal of Pharmaceutical Practice and Service
2024;42(7):278-284
- CountryChina
- Language:Chinese
-
Abstract:
As a new class of acid inhibitors, potassium-competitive acid blocker（P-CAB） inhibits the conformational transition of H+, K+-ATPase with subsequent suppression of H+, K+ exchanging by binding reversibly near the K+ binding site of H+, K+-ATPase, which results in the inhibition of gastric acid secretion in a K+-competitive manner. The unique structure and novel mechanism of P-CAB contribute to the pharmaceutical characteristics superior to other PPIs, making it a new alternative for acid-related diseases（ARDs）. Progress on pharmaceutical characteristics of P-CAB were reviewed in this paper.
